The global intrauterine devices (IUD) market size is expected to value USD 2130 million by 2028 from USD 1686 million in 2023, growing at a CAGR of 4.78% during the forecast period.
The growing awareness of contraception worldwide is one of the key factors driving the growth of the intrauterine devices market. The awareness among people regarding contraception has improved significantly in recent years owing to the increased number of awareness campaigns, educational programs and improved access to information. As a result, the usage of IUDs has increased as these are considered as a reliable and effective contraceptive method. The growing number of initiatives from governmental organizations, non-profit organizations and healthcare organizations on family planning initiatives to address population growth and promote reproductive health contributes to the growth of the intrauterine devices market. An increasing number of public health campaigns and initiatives focussing on women’s health have also boosted the awareness of contraception and increased the adoption of intrauterine devices. The use of social media and digital platforms have also played a significant role in the increasing awareness of contraception including IUDs.
The high efficacy and convenience of intrauterine devices drive market growth. Intrauterine devices are popular for their high effectiveness and the failure rate of IUDs is less than 1%. Considering the high success rate of intrauterine devices, people who want to seek long-term and highly efficient contraception options have been increasingly adopting these devices. The long-acting nature of intrauterine devices further boosts the adoption of these devices. The average protection that IUDs offer ranges from 3 years to 10 years. The long-duration effectiveness of IUDs has been offering sustained contraceptive coverage and peace of mind to users. The convenience and ease of use of intrauterine devices compared to other contraceptive methods further drives the usage of these devices and contribute to market growth.
The growing number of initiatives from several governments aiming to promote family planning, reduce unintended pregnancies and improve women's healthcare access facilities the intrauterine devices market growth. The growing emphasis on women's health and empowerment globally, increasing investments in research and development of female contraceptives, including IUDs, rising population and increasing urbanization in developing countries, increasing demand for effective contraception methods and rising preference from women for non-hormonal contraception options such as IUDs fuel the market’s growth rate.
Continuous advancements in IUD technology, growing healthcare expenditure, improved insurance coverage for contraception, rising incidence of sexually transmitted infections such as HPV and chlamydia, increasing preference for non-invasive and minimally invasive procedures for birth control, growing population and delayed pregnancies and increasing number of collaborations between pharmaceutical companies, healthcare providers and non-profit organizations to increase the availability of IUDs in both developed and developing regions further promote the growth of the intrauterine devices market.
Poor awareness and education regarding IUDs are one of the key factors hampering the market growth. Cultural and societal factors, cost and affordability of intrauterine devices further hinder the market growth, The accessibility and availability challenges and fear of pain and discomfort with the usage of IUDs impede the market growth. Perceived side effects, safety concerns, lack of healthcare provider training and familiarity, religious or ethical opposition, misconceptions and stigma surrounding IUDs further inhibits the growth rate of the global market. The presence of alternative contraceptive options is another significant roadblock to the market’s growth rate.
Impact of COVID-19 on the global intrauterine devices market:
The novel coronavirus originated in Wuhan, China, and has spread to almost every corner of the world. The World Health Organization (WHO) declared an emergency public health issue in March 2020. The COVID-19 pandemic crisis has created a negative impact on contraceptives and the sexual health market. The primary disturbance is created due to the availability of contraceptives among the people—the decrease in the manufacturing and supply quantities of birth control pills worldwide. The incompetence of millions of men and women across the country to access contraceptives during the lockdown period is foreseen to significantly impact reproductive health indicators, including maternal and infant mortality rates. The inadequate access to contraceptives over the best scenario case is to exhibit an extra 1.9 million unwanted pregnancies. Worldwide, 50% of pregnancies are unwanted. The intrauterine contraceptive devices market is expected to have significant growth in the coming years.
Market Size Available
2022 to 2028
2023 to 2028
By Product Type and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
This research report on the global intrauterine devices market has been segmented and sub-segmented based on the product type and region.
Intrauterine Devices Market – By Product Type:
Based on product type, the hormonal intrauterine devices segment is expected to hold the leading share of the global market during the forecast period. The high efficacy and effectiveness of hormonal IUDs are one of the major factors propelling segmental growth. The convenience and ease of use, long-acting reversible contraception and reduction of menstrual bleeding and cramps contribute to the segment’s growth rate. Hormonal benefits, such as alleviating symptoms of endometriosis, growing awareness and acceptance of hormonal contraceptives, rising demand for non-daily contraceptive options, expansion of healthcare coverage and insurance reimbursement and growing prevalence of hormonal contraceptive use further boost the growth of the hormonal IUDs segment.
On the other hand, the copper segment accounted for a considerable share of the market in 2022 and is expected to grow at a steady CAGR during the forecast period. Copper IUDs are a non-hormonal and hormone-free contraception option, which is one of the major factors driving segmental growth. The high efficacy of copper IUDs in preventing pregnancy, growing demand for non-hormonal contraceptive choices, favorable options for women with hormonal sensitivities or contraindications, increasing awareness and preference for non-hormonal contraception and expansion of healthcare coverage and insurance reimbursement further contribute to the segment’s growth rate.
Intrauterine Devices Market – By Region:
North America held the major share of the global market in 2022 and is expected to grow at a healthy CAGR during the forecast period. The growing awareness and acceptance of IUDs as a reliable contraceptive option, favorable government policies and initiatives promoting family planning and reproductive health and growing emphasis on women's healthcare and access to contraception in North America majorly propel the North American intrauterine devices market growth. Technological advancements and availability of advanced IUD options, high healthcare expenditure, insurance coverage and rising preference for long-acting reversible contraception further drive the North American market growth. The U.S. had the leading share of the North American market in 2022 and is expected to register a notable CAGR during the forecast period owing to the growing usage of IUDs and increasing awareness of the benefits of intrauterine devices among the women population of the U.S. As per the data published by the Guttmacher Institute, an estimated 12.6% of the women population in the U.S. aged between 15 to 49 years use IUDs for contraception. The Canadian market is predicted to grow at a healthy CAGR during the forecast period owing to the increasing number of initiatives by the Canadian government. The Canadian government offers universal healthcare coverage that includes IUDs as part of contraceptive services.
Europe held a substantial share of the global market in 2022 and is projected to grow at a noteworthy CAGR during the forecast period. High acceptance and use of IUDs in Europe as a preferred contraceptive method is one of the key factors propelling the European IUDs market growth. The presence of well-established healthcare systems with easy access to reproductive health services and supportive government policies and initiatives promoting family planning and women's health contribute to the European market growth. The rising emphasis on long-acting reversible contraception options, increasing awareness and education on the benefits and effectiveness of IUDs and growing trend of delayed pregnancies and the focus on the spacing between births further fuel the growth rate of the European market. Countries such as Sweden, Denmark, and Norway are estimated to hold the major share of the European market during the forecast period owing to the high usage of IUDs in these countries.
APAC is a lucrative regional market for intrauterine devices and is anticipated to register the highest CAGR during the forecast period. Factors such as a rapidly growing population, increasing need for effective contraception methods, growing number of initiatives and programs from the governments of APAC region promoting family planning and reproductive health, increasing awareness and acceptance of modern contraception options, expansion of healthcare infrastructure and accessibility to reproductive health services primarily drive the growth of the IUDs market in the Asia-Pacific region. Rising focus on women's empowerment and reproductive rights, rapid urbanization and changing lifestyle patterns leading to increased adoption of modern contraception in APAC further boost the growth rate of the APAC market. China and India had the leading share of the APAC market in 2022 and the domination of these countries in the APAC region is expected to continue throughout the forecast period.
Latin America captured a considerable share of the global market in 2022 and is estimated to grow at a healthy growth rate during the forecast period. The growing access to reproductive health services and contraceptive methods and an increasing number of initiatives from the governments of Latin America to promote family planning and reproductive health education majorly drive the Latin American intrauterine devices market growth. The growing awareness of and preference for long-acting reversible contraception and increasing urbanization and changing cultural attitudes toward contraception contribute to the growth of the Latin American market. Brazil and Colombia are predicted to account for the largest share of the Latin American market during the forecast period.
The MEA market is anticipated to hold a moderate share of the global market during the forecast period. Factors such as the growing recognition of the importance of family planning and access to contraception, initiatives from governmental organizations to address population growth and improve maternal and child health, expanding healthcare infrastructure and access to reproductive health services drive the intrauterine devices market growth in MEA. South Africa and Morocco are estimated to play a leading role in the MEA market in the coming years.
KEY MARKET PLAYERS:
Some of the prominent companies leading the global intrauterine devices market profiled in this report are Agile Therapeutics, Actavis PLC, ANI Pharmaceuticals, Inc., Bayer, Teva Pharmaceutical, Besins HealthCare, Brecuro Medical, Effik International, Eurogine, HLL Lifecare, HRA Pharma, Lupin Pharmaceuticals, Ltd., Okamato Industries, Inc., and Pfizer.
RECENT MARKET DEVELOPMENTS:
The global intrauterine devices market was valued at USD 1610 mn in 2022.
The rising awareness and acceptance of contraceptive methods, growing demand for long-acting and reversible contraceptives, and government initiatives to increase access to family planning services are majorly propelling the growth of the intrauterine devices market.
Bayer AG, Teva Pharmaceuticals, Allergan plc, CooperSurgical, and Merck & Co., Inc. are some of the notable companies in the intrauterine devices market.
Asia-Pacific is expected to witness significant growth in the market, owing to the large population base, increasing awareness about contraceptives, and growing adoption of family planning programs.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]